<\/p>\n
Since 2004, bioelectrical impedance analysis (BIA) has been mentioned in some twenty clinical practice guidelines issued by international scientific societies (ESPEN, ASPEN, GLIM), national health authorities (HAS in France), and pathology-specific societies (ERS for COPD, AND for cystic fibrosis and HIV). The complete summary table can be consulted here. This progressive integration into reference frameworks has not been without debate: some scientific societies initially expressed reservations before evolving their position as the scientific literature expanded\u2014a point detailed below.<\/p>\n
Before tracing this recognition, it is useful to recall that the adoption of BIA was neither unanimous nor immediate. In 2019, a systematic review by ASPEN10<\/sup><\/a> could not yet recommend its systematic use, due to the heterogeneity of devices and proprietary equations, as well as their limited validation across populations. More recently, the 2025-2026 series of methodological standards16<\/sup><\/a>,17<\/sup><\/a> still highlights that the proprietary algorithms of certain devices are not entirely transparent, which requires a cautious and contextualized interpretation of the results. It is precisely this demand for methodological rigor that, over the years, has structured the integration of BIA into guidelines\u2014rather than an uncritical adoption.<\/p>\n Between 2002 and 2004, ESPEN (European Society for Clinical Nutrition and Metabolism) brought together an international working group of BIA experts\u2014including Kyle, Deurenberg, Elia, Scharfetter, and Pichard, authors of several reference equations and methods. The objective: to critically evaluate the available data to establish the physical foundations of the method, specify its performance, indications, limitations, and the conditions for standardized use.<\/p>\n This work resulted in two complementary publications in Clinical Nutrition<\/em> in 2004: Bioelectrical impedance analysis \u2014 Part I: Review of Principles and Methods<\/em>1<\/sup><\/a> and Part II: Utilization in Clinical Practice<\/em>2<\/sup><\/a>. These two texts remain foundational references for the standardization of BIA today.<\/p>\n BIA is now primarily integrated into the diagnostic algorithms for malnutrition and obesity. In 2016, four major international scientific societies\u2014ESPEN, ASPEN, FELANPE (Latin America), and PENSA (Asia)\u2014created the Global Leadership Initiative on Malnutrition<\/em> (GLIM) to harmonize the diagnosis of malnutrition in adults worldwide.<\/p>\n Published in 2019, the GLIM criteria3<\/sup><\/a> standardized this diagnosis and recognized BIA as a method for assessing muscle mass, via two indicators: the Fat-Free Mass Index<\/em> (FFMI) and the Appendicular Skeletal Muscle Index<\/em> (ASMI), for which cutoff values were proposed. The 20224<\/sup><\/a> and 20255<\/sup><\/a> updates, published in Clinical Nutrition<\/em> and JPEN<\/em>, have maintained BIA among the usable methods for this criterion.<\/p>\n Figure \u2014 The major milestones in the recognition of BIA in clinical practice guidelines, from 2004 to 2026.<\/em><\/p>\n In 2015, within the framework of malnutrition diagnosis, ESPEN mentions the FFMI6<\/sup><\/a>. In 2017, its publication on definitions and terminology in clinical nutrition7<\/sup><\/a> recommends BIA for the assessment of malnutrition, sarcopenia, and sarcopenic obesity, as well as for patient monitoring during treatment\u2014with an agreement rate of 97% among the consulted experts, one of the highest in this body of recommendations. The same year, ESPEN formulated specific recommendations for an objective assessment of muscle mass in cancer patients8<\/sup><\/a>.<\/p>\n ASPEN’s position has progressively refined. Following the 2019 reservation mentioned above, the evolution of available data led to a more favorable stance on BIA: the 2022 GLIM guidelines4<\/sup><\/a> explicitly recognize it as a method for assessing skeletal muscle mass, provided the interpretation is adapted to the clinical context.<\/p>\n Also in 2022, ESPEN and the European Association for the Study of Obesity (EASO) established a consensus on the diagnosis of sarcopenic obesity\u2014the coexistence of excess adiposity and decreased muscle mass and function\u2014integrating fat mass (%FM) and skeletal muscle mass adjusted for weight (SMM\/W), both of which can be assessed by BIA9<\/sup><\/a>.<\/p>\n Nutritional assessment by BIA has also been studied in specific pathological contexts:<\/p>\n The series of publications initiated in 2025 by Prado, Heymsfield, Gonzalez, and Norman16<\/sup><\/a>,17<\/sup><\/a>, bringing together nearly 30 international body composition experts, addresses a recurring problem: the terminological and methodological confusion surrounding body composition assessment. It returns to the foundations of the discipline\u2014levels of body organization, harmonized terminology\u2014and details, for each method (bioimpedance, DXA, CT, ultrasound), its principles, validity, reliability, and limitations. It notably distinguishes clearly between BIA (SF\/MF) and BIS, and recalls the limitations related to proprietary algorithms mentioned earlier.<\/p>\n In France, the HAS (Haute Autorit\u00e9 de Sant\u00e9), in collaboration with the French Federation of Nutrition (FFN), has published several good practice guidelines integrating BIA: for malnutrition in people aged 70 and over in 202118<\/sup><\/a>, for adults under 70 in 201919<\/sup><\/a>, and for adult obesity in 202220<\/sup><\/a>. The parameters FM%, SMM\/W, FFMI, and ASMI are explicitly included.<\/p>\n The integration of BIA into the recommendations of scientific societies and health authorities has been built progressively, over twenty years, with assumed stages of caution (ASPEN 2019) as well as strong consensus (ESPEN 2017, 97% agreement). It is this trajectory\u2014rather than the endorsement of a single society\u2014that constitutes the strongest argument for a practitioner still wondering about the place of this tool in their practice.<\/p>\n2004: ESPEN lays the methodological foundations of bioelectrical impedance analysis<\/h2>\n
2016-2019: GLIM harmonizes the diagnosis of malnutrition<\/h2>\n
2015-2017: ESPEN broadens the scope of application<\/h2>\n
2019-2022: From caution to recognition for ASPEN and sarcopenic obesity<\/h2>\n
Specific applications by pathology<\/h2>\n
\n
2025-2026: A methodological reset by a collective of experts<\/h2>\n
The place of BIA in French recommendations<\/h2>\n
In summary<\/h2>\n